138 related articles for article (PubMed ID: 36099888)
1. Absolute Lymphocyte Count as an Independent Prognostic Factor in Metastatic Breast Cancer: A Retrospective Study.
Sawa A; Bando H; Kamohara R; Takeuchi N; Terasaki A; Okazaki M; Iguchi-Manaka A; Hara H
Oncology; 2022; 100(11):591-601. PubMed ID: 36099888
[TBL] [Abstract][Full Text] [Related]
2. Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count With Clinical Outcomes in Advanced Breast Cancer in the MONARCH 2 Trial.
Tokunaga E; Miyoshi Y; Dozono K; Kawaguchi T; Toi M
Oncologist; 2024 Mar; 29(3):e319-e329. PubMed ID: 37971418
[TBL] [Abstract][Full Text] [Related]
3. Absolute lymphocyte count decreases with disease progression and is a potential prognostic marker for metastatic breast cancer.
Jimbo H; Horimoto Y; Ishizuka Y; Nogami N; Shikanai A; Saito M; Watanabe J
Breast Cancer Res Treat; 2022 Nov; 196(2):291-298. PubMed ID: 36156756
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of absolute lymphocyte count and neutrophil-to-lymphocyte ratio for patients with metastatic breast cancer: a systematic review and meta-analysis.
Sang B; Fan Y; Wang X; Dong L; Gong Y; Zou W; Zhao G; He J
Front Oncol; 2024; 14():1360975. PubMed ID: 38515567
[TBL] [Abstract][Full Text] [Related]
5. Utility of the Absolute Lymphocyte Count and Neutrophil/Lymphocyte Ratio for Predicting Survival in Patients with Metastatic Breast Cancer on Eribulin: A Real-World Observational Study.
Ueno A; Maeda R; Kin T; Ito M; Kawasaki K; Ohtani S
Chemotherapy; 2019; 64(5-6):259-269. PubMed ID: 32305977
[TBL] [Abstract][Full Text] [Related]
6. Absolute Lymphocyte Count Is an Independent Prognostic Factor for ER-positive HER2-negative Advanced Breast Cancer Patients Treated With CDK4/6 Inhibitors.
Kanaoka H; Nagahashi M; Atake Y; Hattori A; Bun A; Fukui R; Ozawa H; Fujimoto Y; Higuchi T; Natori K; Imamura M; Murase K; Takatsuka Y; Miyoshi Y
Anticancer Res; 2022 Oct; 42(10):4867-4878. PubMed ID: 36192009
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil-Lymphocyte Ratio and Absolute Lymphocyte Count as Prognostic Markers in Patients Treated with Curative-intent Radiotherapy for Non-small Cell Lung Cancer.
Punjabi A; Barrett E; Cheng A; Mulla A; Walls G; Johnston D; McAleese J; Moore K; Hicks J; Blyth K; Denholm M; Magee L; Gilligan D; Silverman S; Qureshi M; Clinch H; Hatton M; Philipps L; Brown S; O'Brien M; McDonald F; Faivre-Finn C; Hiley C; Evison M
Clin Oncol (R Coll Radiol); 2021 Aug; 33(8):e331-e338. PubMed ID: 33863615
[TBL] [Abstract][Full Text] [Related]
8. Monitoring trends in the absolute lymphocyte count and the neutrophil-to-lymphocyte ratio in patients with breast cancer receiving eribulin.
Su MX; Lin HW; Nguyen HTH; Lin TC; Chen CJ; Wang HC; Wu CT; Wu YC; He GY; Liu LC; Huang CH
BMC Cancer; 2024 Feb; 24(1):195. PubMed ID: 38347468
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment Absolute Lymphocyte Count and Neutrophil-to-lymphocyte Ratio Are Prognostic Factors for Stage III Breast Cancer.
Yamanouchi K; Maeda S; Takei D; Koga Y; Yamashita M; Hamada T; Hirayama T; Yoneda A; Tokunaga T; Takeshita H; Kuroki T
Anticancer Res; 2021 Jul; 41(7):3625-3634. PubMed ID: 34230159
[TBL] [Abstract][Full Text] [Related]
10. High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician's choice-in the EMBRACE study.
Miyoshi Y; Yoshimura Y; Saito K; Muramoto K; Sugawara M; Alexis K; Nomoto K; Nakamura S; Saeki T; Watanabe J; Perez-Garcia JM; Cortes J
Breast Cancer; 2020 Jul; 27(4):706-715. PubMed ID: 32133606
[TBL] [Abstract][Full Text] [Related]
11. A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab.
Hong J; Chen X; Gao W; Zhu S; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Fei X; Lin L; Shen K
Cancer Manag Res; 2019; 11():3371-3379. PubMed ID: 31114373
[No Abstract] [Full Text] [Related]
12. Utility of Follow-up With Absolute Lymphocyte Count in Patients Undergoing Eribulin Treatment for Early Detection of Progressive Advanced or Metastatic Breast Cancer.
Goto W; Kashiwagi S; Takada K; Asano Y; Morisaki T; Shibutani M; Tanaka H; Hirakawa K; Ohira M
Anticancer Res; 2022 Feb; 42(2):939-946. PubMed ID: 35093893
[TBL] [Abstract][Full Text] [Related]
13. Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.
Araki K; Ito Y; Fukada I; Kobayashi K; Miyagawa Y; Imamura M; Kira A; Takatsuka Y; Egawa C; Suwa H; Ohno S; Miyoshi Y
BMC Cancer; 2018 Oct; 18(1):982. PubMed ID: 30326862
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of Prognostic Factors Considering Absolute Lymphocyte Count of Metastatic Breast Cancer Patients with Eribulin Mesylate Therapy-A Retrospective Study in a Single Institution].
Ueda Y; Makino Y; Hidaka H; Nakamura T; Beppu K; Ohuchida J; Odate S; Terasaka S; Nishida T; Yoshida M; Kimura R; Shingaki K; Nakanishi Y; Inomata M; Mine Y; Katayose K; Marutsuka K; Otomo N
Gan To Kagaku Ryoho; 2022 Nov; 49(11):1229-1232. PubMed ID: 36412026
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil-lymphocyte ratio in metastatic breast cancer is not an independent predictor of survival, but depends on other variables.
Ivars Rubio A; Yufera JC; de la Morena P; Fernández Sánchez A; Navarro Manzano E; García Garre E; García Martinez E; Marín Zafra G; Sánchez Cánovas M; García Torralba E; Ayala de la Peña F
Sci Rep; 2019 Nov; 9(1):16979. PubMed ID: 31740715
[TBL] [Abstract][Full Text] [Related]
16. Absolute Lymphocyte Count Changes During Neoadjuvant Chemotherapy are Associated With Prognosis of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Patients.
Miyamoto N; Inoue H; Inui T; Sasa S; Aoyama M; Okumura K; Toba H; Hino N; Nishisho A; Yukishige S; Kawanaka T; Takizawa H; Tangoku A
Clin Breast Cancer; 2023 Apr; 23(3):e68-e76. PubMed ID: 36682907
[TBL] [Abstract][Full Text] [Related]
17. A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience.
Watanabe J; Saito M; Horimoto Y; Nakamoto S
Breast Cancer Res Treat; 2020 May; 181(1):211-220. PubMed ID: 32249370
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in inflammatory breast cancer.
Al Jarroudi O; El Bairi K; Abda N; Zaimi A; Jaouani L; Chibani H; Afqir S
Biomark Med; 2021 Oct; 15(14):1289-1298. PubMed ID: 34486882
[No Abstract] [Full Text] [Related]
19. Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer.
Shao B; Liu X; Li H; Song G; Di L; Jiang H; Yan Y; Zhang R; Ran R; Zhang J; Liu Y; Wang H; Wang J
Curr Oncol; 2022 Aug; 29(9):6154-6166. PubMed ID: 36135052
[TBL] [Abstract][Full Text] [Related]
20. C-Reactive Protein and Absolute Lymphocyte Count Can Predict Overall Survival of Patients Treated With Eribulin.
Sata A; Fukui R; Miyagawa Y; Bun A; Ozawa H; Fujimoto Y; Higuchi T; Imamura M; Miyoshi Y
Anticancer Res; 2020 Jul; 40(7):4147-4156. PubMed ID: 32620664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
